Immunization targeting a minor plaque constituent clears β-amyloid and rescues behavioral deficits in an Alzheimer's disease mouse model

Neurobiology of Aging

Volumn 34, Issue 1, 2013, Pages 137-145

  Morales Corraliza, Jose ^a,b   Schmidt, Stephen D ^a,e   Mazzella, Matthew J ^a   Berger, Jason D ^a   Wilson, Donald A ^a,b,c   Wesson, Daniel W ^a,f   Jucker, Mathias ^d   Levy, Efrat ^a,b   Nixon, Ralph A ^a,b   Mathews, Paul M ^a,b  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

A ; Alzheimer's disease; Codeposition; Immunization; Immunotherapy

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; MONOCLONAL ANTIBODY M3.2; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; HABITUATION; IMMUNOPRECIPITATION; IMMUNOTHERAPY; MOUSE; NESTING; NONHUMAN; ODOR; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN TARGETING;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIBODIES, MONOCLONAL; BEHAVIORAL SYMPTOMS; BRAIN; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MICE; MICE, TRANSGENIC; MUTATION; NESTING BEHAVIOR; ODORS; OLFACTION DISORDERS; PRESENILIN-1; STATISTICS, NONPARAMETRIC;

EID: 84868113477     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2012.04.007     Document Type: Article

References (49)

1. Bayer A.J., Bullock R., Jones R.W., Wilkinson D., Paterson K.R., Jenkins L., Millais S.B., Donoghue S. Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD. Neurology 2005, 64:94-101.
2. Bodin K., Ellmerich S., Kahan M.C., Tennent G.A., Loesch A., Gilbertson J.A., Hutchinson W.L., Mangione P.P., Gallimore J.R., Millar D.J., Minogue S., Dhillon A.P., Taylor G.W., Bradwell A.R., Petrie A., Gillmore J.D., Bellotti V., Botto M., Hawkins P.N., Pepys M.B. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 2010, 468:93-97.
3. Cataldo A.M., Nixon R.A. Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:3861-3865.
4. Chishti M.A., Yang D.S., Janus C., Phinney A.L., Horne P., Pearson J., Strome R., Zuker N., Loukides J., French J., Turner S., Lozza G., Grilli M., Kunicki S., Morissette C., Paquette J., Gervais F., Bergeron C., Fraser P.E., Carlson G.A., George-Hyslop P.S., Westaway D. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. 2001, 276:21562-21570.
5. Choi-Miura N.H., Ihara Y., Fukuchi K., Takeda M., Nakano Y., Tobe T., Tomita M. SP-40,40 is a constituent of Alzheimer's amyloid. Acta Neuropathol. 1992, 83:260-264.
6. Citron M. Alzheimer's disease: strategies for disease modification. Nat. Rev. Drug Discov. 2010, 9:387-398.
7. Cramer P.E., Cirrito J.R., Wesson D.W., Lee C.Y., Karlo J.C., Zinn A.E., Casali B.T., Restivo J.L., Goebel W.D., James M.J., Brunden K.R., Wilson D.A., Landreth G.E. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science 2012, 335:1503-1506.
8. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., Holtzman D.M. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:8850-8855.
9. Doty R.L. Olfactory capacities in aging and Alzheimer's disease. Psychophysical and anatomic considerations. Ann. N. Y. Acad. Sci. 1991, 640:20-27.
10. Duff K., Eckman C., Zehr C., Yu X., Prada C.M., Perez-tur J., Hutton M., Buee L., Harigaya Y., Yager D., Morgan D., Gordon M.N., Holcomb L., Refolo L., Zenk B., Hardy J., Younkin S. Increased Aβ42(43) in brains of mice expressing mutant presenilin 1. Nature 1996, 383:710-713.
11. Fung J., Frost D., Chakrabartty A., McLaurin J. Interaction of human and mouse Aβ peptides. J. Neurochem. 2004, 91:1398-1403.
12. Gauthier S., Kaur G., Mi W., Tizon B., Levy E. Protective mechanisms by cystatin C in neurodegenerative diseases. Front. Biosci. (Schol. Ed.) 2011, 3:541-554.
13. Giannakopoulos P., Kövari E., French L.E., Viard I., Hof P.R., Bouras C. Possible neuroprotective role of clusterin in Alzheimer's disease: a quantitative immunocytochemical study. Acta Neuropathol. 1998, 95:387-394.
14. Herzig M.C., Winkler D.T., Burgermeister P., Pfeifer M., Kohler E., Schmidt S.D., Danner S., Abramowski D., Stürchler-Pierrat C., Bürki K., van Duinen S.G., Maat-Schieman M.L., Staufenbiel M., Mathews P.M., Jucker M. Aβ is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat. Neurosci. 2004, 7:954-960.
15. Holcomb L., Gordon M.N., McGowan E., Yu X., Benkovic S., Jantzen P., Wright K., Saad I., Mueller R., Morgan D., Sanders S., Zehr C., O'Campo K., Hardy J., Prada C.M., Eckman C., Younkin S., Hsiao K., Duff K. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 1998, 4:97-100.
16. Holmes C., Boche D., Wilkinson D., Yadegarfar G., Hopkins V., Bayer A., Jones R.W., Bullock R., Love S., Neal J.W., Zotova E., Nicoll J.A. Long-term effects of Aβ42 immunization in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008, 372:216-223.
17. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
18. Jankowsky J.L., Younkin L.H., Gonzales V., Fadale D.J., Slunt H.H., Lester H.A., Younkin S.G., Borchelt D.R. Rodent Aβ modulates the solubility and distribution of amyloid deposits in transgenic mice. J. Biol. Chem. 2007, 282:22707-22720.
19. Kaeser S.A., Herzig M.C., Coomaraswamy J., Kilger E., Selenica M.L., Winkler D.T., Staufenbiel M., Levy E., Grubb A., Jucker M. Cystatin C modulates cerebral β-amyloidosis. Nat. Genet. 2007, 39:1437-1439.
20. Lemere C.A., Masliah E. Can Alzheimer disease be prevented by β-amyloid immunotherapy?. Nat. Rev. Neurol. 2010, 6:108-119.
21. Leveugle B., Scanameo A., Ding W., Fillit H. Binding of heparan sulfate glycosaminoglycan to β-amyloid peptide: inhibition by potentially therapeutic polysulfated compounds. Neuroreport 1994, 5:1389-1392.
22. Levy E., Jaskolski M., Grubb A. The role of cystatin C in cerebral amyloid angiopathy and stroke: cell biology and animal models. Brain Pathol. 2006, 16:60-70.
23. Mathews P.M., Cataldo A.M., Kao B.H., Rudnicki A.G., Qin X., Yang J.L., Jiang Y., Picciano M., Hulette C., Lippa C.F., Bird T.D., Nochlin D., Walter J., Haass C., Lévesque L., Fraser P.E., Andreadis A., Nixon R.A. Brain expression of presenilins in sporadic and early-onset, familial Alzheimer's disease. Mol. Med. 2000, 6:878-891.
24. McGeer P.L., Kawamata T., Walker D.G. Distribution of clusterin in Alzheimer brain tissue. Brain Res. 1992, 579:337-341.
25. Mi W., Jung S.S., Yu H., Schmidt S.D., Nixon R.A., Mathews P.M., Tagliavini F., Levy E. Complexes of β-amyloid and cystatin C in the human central nervous system. J. Alzheimers Dis. 2009, 18:273-280.
26. Mi W., Pawlik M., Sastre M., Jung S.S., Radvinsky D.S., Klein A.M., Sommer J., Schmidt S.D., Nixon R.A., Mathews P.M., Levy E. Cystatin C inhibits β-amyloid deposition in Alzheimer's disease mouse models. Nat. Genet. 2007, 39:1440-1442.
27. Morales-Corraliza J., Mazzella M.J., Berger J.D., Diaz N.S., Choi J.H., Levy E., Matsuoka Y., Planel E., Mathews P.M. In vivo turnover of tau and APP metabolites in the brains of wild-type and Tg2576 mice: greater stability of sAPP in the β-amyloid depositing mice. PLoS One 2009, 4:e7134.
28. Murphy C. Loss of olfactory function in dementing disease. Physiol. Behav. 1999, 66:177-182.
29. Namba Y., Tomonaga M., Kawasaki H., Otomo E., Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 1991, 541:163-166.
30. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., Weller R.O. Neuropathology of human Alzheimer disease after immunization with β-amyloid peptide: a case report. Nat. Med. 2003, 9:448-452.
31. Nixon R.A., Cataldo A.M. Lysosomal system pathways: genes to neurodegeneration in Alzheimer's disease. J. Alzheimers Dis. 2006, 9(3 suppl):277-289.
32. Perry G., Friedman R., Shaw G., Chau V. Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:3033-3036.
33. Pype S., Moechars D., Dillen L., Mercken M. Characterization of β-amyloid peptides from brain extracts of transgenic mice overexpressing the London mutant of human amyloid precursor protein. J. Neurochem. 2003, 84:602-609.
34. Richey P.L., Siedlak S.L., Smith M.A., Perry G. Apolipoprotein E interaction with the neurofibrillary tangles and senile plaques in Alzheimer disease: implications for disease pathogenesis. Biochem. Biophys. Res. Commun. 1995, 208:657-663.
35. Rozmahel R., Huang J., Chen F., Liang Y., Nguyen V., Ikeda M., Levesque G., Yu G., Nishimura M., Mathews P., Schmidt S.D., Mercken M., Bergeron C., Westaway D., St George-Hyslop P. Normal brain development in PS1 hypomorphic mice with markedly reduced γ-secretase cleavage of AβPP. Neurobiol. Aging 2002, 23:187-194.
36. Rozmahel R., Mount H.T., Chen F., Nguyen V., Huang J., Erdebil S., Liauw J., Yu G., Hasegawa H., Gu Y., Song Y.Q., Schmidt S.D., Nixon R.A., Mathews P.M., Bergeron C., Fraser P., Westaway D., George-Hyslop P.S. Alleles at the Nicastrin locus modify presenilin 1-deficiency phenotype. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:14452-14457.
37. Saido T.C., Iwatsubo T., Mann D.M., Shimada H., Ihara Y., Kawashima S. Dominant and differential deposition of distinct β-amyloid peptide species, AβN3(pE), in senile plaques. Neuron 1995, 14:457-466.
38. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with β-amyloid attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
39. Schmidt S.D., Jiang Y., Nixon R.A., Mathews P.M. Tissue processing prior to protein analysis and amyloid-β quantitation. Methods Mol. Biol. 2005, 299:267-278.
40. Schmidt S.D., Nixon R.A., Mathews P.M. ELISA method for measurement of amyloid-β levels. Methods Mol. Biol. 2005, 299:279-297.
41. Simpson J.E., Ince P.G., Lace G., Forster G., Shaw P.J., Matthews F., Savva G., Brayne C., Wharton S.B. Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain. Neurobiol. Aging 2010, 31:578-590.
42. Sundberg H., Døving K., Novikov S., Ursin H. A method for studying responses and habituation to odors in rats. Behav. Neural Biol. 1982, 34:113-119.
43. Wesson D.W., Levy E., Nixon R.A., Wilson D.A. Olfactory dysfunction correlates with β-amyloid burden in an Alzheimer's disease mouse model. J. Neurosci. 2010, 30:505-514.
44. Wesson D.W., Wilson D.A. Age and gene overexpression interact to abolish nesting behavior in Tg2576 amyloid precursor protein (APP) mice. Behav. Brain Res. 2011, 216:408-413.
45. Wilcock D.M., DiCarlo G., Henderson D., Jackson J., Clarke K., Ugen K.E., Gordon M.N., Morgan D. Intracranially administered anti-Aβ antibodies reduce β-amyloid deposition by mechanisms both independent of and associated with microglial activation. J. Neurosci. 2003, 23:3745-3751.
46. Wilson D.A., Linster C. Neurobiology of a simple memory. J. Neurophysiol. 2008, 100:2-7.
47. Wisniewski T., Frangione B. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci. Lett. 1992, 135:235-238.
48. Zheng H., Jiang M., Trumbauer M.E., Sirinathsinghji D.J., Hopkins R., Smith D.W., Heavens R.P., Dawson G.R., Boyce S., Conner M.W., Stevens K.A., Slunt H.H., Sisoda S.S., Chen H.Y., Van der Ploeg L.H. β-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell 1995, 81:525-531.
49. Zotova E., Nicoll J.A., Kalaria R., Holmes C., Boche D. Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy. Alzheimers Res. Ther. 2010, 2:1.